Infographic: What is CAR-T Cell Therapy & How Does it Fight Cancer? By Clara Rodríguez Fernández 2 minutesmins October 18, 2017 -Updated: onMarch 25, 2024 2 minutesmins Share WhatsApp Twitter Linkedin Email Newsletter Signup - Under Article / In Page"*" indicates required fieldsCommentsThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Business email* Everything you need to know about CAR-T, a revolutionary cell therapy for cancer.You might have heard of CAR-T cell therapy as a “miracle cure” for cancer. The approval of Novartis’ Kymriah, the first CAR-T therapy, made headlines in August as it was the first gene-edited cell therapy for cancer to make it to the market. The approval of Gilead and Kite Pharma’s CAR-T therapy Yescarta followed this week, leading the way for many other versions that are expected to arrive on the market in coming years to treat different types of cancer, with better efficacy and safety, and lower prices.Companies like Juno Therapeutics, Cellectis, Celyad, Bluebird bio, and Celgene are already working on it and the number of clinical trials testing the technology is booming. In the next decade, CAR-T cells are expected to change how cancer is treated and start turning it into a much more manageable diagnosis.But, exactly, what is CAR-T? How does it work? Can it really cure cancer? Does it have side effects? How much does it cost? You’ll find all the answers in this great infographic by Etienne Raimondeau. [Click here for the HQ version]Etienne Raimondeau just completed his PhD in Biochemistry & Structural Biology at EMBL. When not pipetting, he enjoys communicating science through illustrations! You can find more of his work here. Organoids in cancer research: Paving the way for faster drug development across cancer indications This webinar explores how patient-derived organoids (PDOs) are redefining oncology research. Discover how advanced, well-characterized models empower researchers to streamline candidate selection, accelerate orphan drug programs, and deliver transformative therapies to patients faster than ever. Watch now Explore other topics: CancerCAR-T ADVERTISEMENT